|
24 Haymarket
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$0 - $5 million, $5 - $10 million, $15 - $20 million, Over $20 million
|
Europe
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Seed, Series A, Series B-Z
|
blood-borne diseases, in-vitro liver and metabolic disease, degenerative diseases, harmful cells, bacteria, toxins, and inflammatory cytokines, directly from a patient’s bloodstream, allergic disease, food allergy, rheumatoid arthritis, ulcerative colitis, EOE, otology, opthalmology
|
Cell therapies, Small molecules and peptides
|
Headquartered in London and with a regional office in Edinburgh, we are distinguished by the calibre and engagement of the 24Haymarket Investor Network.
We follow a strict investment thesis with a focus on verticals in the nascent stages of high growth where we can leverage proprietary insight from our Investor Network.
We focus on investing in companies that have demonstrated initial commercial traction.
We adhere to an active investment philosophy with a right to a board seat in each investment we pursue combined with an involved post-investment model.
3,000+ Years of collective entrepreneurial, investment and operational experience
100+ Sophisticated, engaged private investors
£104m Syndicate members' own capital invested
£1-£5m Initial investment with follow-on ambition and capacity
56 Lead investments
18% Average ownership
OUR VALUES:
* Connectivity - Thousands of years of collective experience.
*Alignment - Direct financial commitment to each of our investments.
*Transparency - We aim to complete within 6 weeks of first conversation.
*Partnership - We seek to optimise each investment we make.
|
|
4BIO Capital
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America, Asia
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D
|
Seed, Series A, Series B-Z, IPO or Public
|
all monogenic disorders, gain-of-function disorders, oncology, autoimmune disorders, genetic diseases, metabolic diseases, haematological malignancies, inflammatory disorders, disorders of the HSC lineage, rare genetic diseases, neurology, cancer, infectious disease, blinding diseases, solid tumors, blinding inherited retinal diseases, mitochondrial and related diseases, genotype agnostic, stargardt’s disease, obsteric, cardiovascular, immunology, CNS,
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Microbiome therapies, Protein degradation
|
4BIO Capital is a London-based venture capital firm focused solely on the advanced therapies sector.
4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients.
Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
The 4BIO team comprises leading advanced therapy scientists and experienced life science investors; in total, they have published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine.
Accordingly, 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that separate the very best investment opportunities.
|
|
5AM Ventures
|
Menlo Park
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million, $0 - $5 million, $10 - $15 million, $15 - $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million, $1 - 3 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
brain disorders, inflammatory, metabolic, neurological diseases, rare diseases that target the endocrine system, immuno-oncology, hematologic diseases, rare blood disorders, oral medicines for severe RNA-mediated diseases, enteric hyperoxaluria, irritable bowel syndrome, IBD, neurological diseases, infectious diseases, cancer, autism spectrum disorder, schizophrenia, Alzheimer's disease, dyskinesia, Parkinson's disease, hyperactivity or impulsivity, glaucoma, chronic kidney disease, obesity, Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Atopic Dermatitis, Cholestatic Pruritus, Uremic Pruritus, anemia, urea cycle disorders, primary biliary cholangitis, genetic epilepsy, multifocal motor neuropathy, dementia, erosive esophagitis, gastroparesis, neuromuscular disease, severe asthma, pediatric liver disease, alcoholic liver disease with cirrhosis, Wilson's fulminant disease, hepatitis, lupus, mucosal, myasthenia
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines, Protein degradation, Radiopharmacueticals
|
5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors.
We believe our time tested approach combined with a knowledgeable team provides us with a competitive edge to find and shape life science companies around the world.
Innovative strategy defines our core values and our commitment to our partners.
5AM’s portfolio of advanced life science technologies is diversified within the healthcare industry’s biopharmaceutical, drug delivery technology and research instrument sectors. Within each sector, 5AM evaluates innovative platform technologies, corporate spin-offs and products with shorter development cycles and invests across multiple therapeutic areas.
Hands on approach to company building
5AM is driven by the “old-fashioned” VC style of working closely with portfolio companies. Going beyond passive board roles, ours is unusually hands-on when starting companies, assuming short-term operating roles and proactively providing guidance throughout a portfolio company’s life. Our team's input to operating plans, strategy and management team development has a major impact on creating and realizing shareholder value.
Putting the team in place
Our professionals have spent their careers in the life science industry, often working together over many years while helping to create shareholder value. Team members draw upon over a century of combined operational experience as CEOs and other leadership roles at life science companies. We believe this positions us as an “entrepreneur-friendly” firm and validates our taking an active role when mentoring entrepreneurs. We strive to identify the best scientists in leading-edge fields, work with well-established entrepreneurs, and co-invest with value-added venture capitalists and partners at major life science companies.
Capital efficiency & shortened realization time
Our investments are expected to generate attractive returns within three to five years driven by validated development-stage assets and by technologies with less regulated commercialization paths. We work to maximize equity returns by sourcing non-equity capital and by creating earlier exit opportunities. This may involve accessing capital from governmental agencies, building strategic alliances with large life science companies or acquiring later-stage products.
Focus on low loss rate
We strive to maximize shareholder returns for all portfolio companies, unlike many venture capitalists that focus on their best investments. 5AM seeks to redefine business strategy, restructures management teams and accesses additional assets to enhance individual company performance and overall fund returns. Our low loss rates demonstrate our strategy’s inherent value and have had a very positive impact on overall returns.
5AM Opportunities
The 5AM Opportunities funds are later-stage funds which invest in both existing 5AM portfolio companies and non-5AM companies in the private and public markets.
Diversity, Equity and Inclusion
At the intersection of life science and venture capital, 5AM is committed to diversity, equity and inclusion as a core principle in catalyzing breakthrough science. By leveraging diverse backgrounds, abilities, and perspectives both in our firm and portfolio, we strive to be leaders in our industry by bravely embracing diversity to enable the development of transformative therapies for ALL patients.
|
|
8VC
|
San Francisco
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million, $0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million
|
Europe, North America, Middle East Africa Rest of the World
|
505(b)1
|
$5 - 15 million, Over $15 million, Under $1 million, $1 - 3 million, $3 - 5 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
cancer, autoimmune diseases, immuno-oncology, liver cancer, colon cancer, lung cancer, breast cancer, lymphoma, metabolic diseases, immune dysfunction, cardiovascular diseases, solid tumors, blood cancers, eye diseases, CNS diseases, AML, CRC, HCC, MDS, rheumatoid arthritis, hidradenitis suppurativa, ulcerative colitis, Crohn's disease, ALL, MF, MPAL, elderly patients, pediatric patients, acute leukemias, debilitating diseases, genetic diseases, atopic dermatitis, cystic fibrosis
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Microbiome therapies, Protein degradation, Vaccines
|
At 8VC, we partner with elite founders to build transformational technologies that create long-term economic and societal value.
We are investors who never stopped being engineers, operators, policymakers, philosophers, and entrepreneurs. We are equally fervent realists and optimists, with an irreverence for convention and a reverence for wisdom.
We are fiduciaries and stewards to our limited partners and also to our principles, our firm, and the innovation ecosystem. Our work matters and we are building for the long term.
Success, in all its forms, gives rise to more success. If we forget about getting our share, and focus on doing our part, we can all prosper.
Being different gets attention. Being different, and right, can change the world.
We believe in the American experiment, that its ideals are worth striving for and its people and institutions are worth defending.
|
|
A16z
|
Menlo Park
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
cancer, autoimmune, oncology, monogenic diseases, inflammatory diseases, immunology, urea cycle disorders, primary biliary cholangitis, metabolic, rare diseases, genetic epilepsy, neurodegenerative diseases, genetic diseases, neuroinflammation, dermatology, nephrology, cardiology, hepatology, gastroenterology,
|
Cell therapies, Gene therapies, Large molecules (biologics), Protein degradation, Small molecules and peptides, Vaccines
|
Andreessen Horowitz (aka a16z) is a venture capital firm that backs bold entrepreneurs building the future through technology. We are stage agnostic. We invest in seed to venture to growth-stage technology companies, across AI, bio + healthcare, consumer, crypto, enterprise, fintech, games, and companies building toward American dynamism. a16z has $35B in assets under management across multiple funds.
Respect for the entrepreneur and the company-building process defines a16z. We know what it’s like to be in the founder’s shoes. General partners lead the firm, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, and have domain expertise ranging from data to artificial intelligence, biology to crypto, distributed systems to security, and marketplaces to financial services.
We aim to connect entrepreneurs, investors, executives, engineers, academics, industry experts, cultural geniuses, and others in the technology ecosystem. We have built a network of experts, including technical and executive talent; marketing and communications resources; Fortune 500/Global 2000 companies; cultural leaders and influencers; as well as other technology decision makers and key opinion leaders. Our network reflects a16z’s commitment to helping our portfolio companies grow their businesses, and our operating teams provide entrepreneurs with access to expertise and insights across the entire spectrum of company-building.
|
|
AbbVie Biotech Ventures
|
San Francisco CA, Cambridge MA, United Kingdom
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic
|
Seed, Series A, Series B
|
gastro-intestinal diseases, Cancer, Solid Tumor, Prostate Cancer, Diabetes, Crohn's disease, ulcerative colitis, Endometrial cancer, Parkinson's disease, Gaucher disease, Frontotemporal dementia,
|
Cell therapies, Gene therapies, Protein degradation, Small molecules and peptides
|
AbbVie Ventures
As tomorrow’s innovations are developed by today’s entrepreneurs, we invest in transformational scientific opportunities aligned with our core R&D interests to gain access to next-generation science and build relationships with proven and emerging scientific leaders.
we focus exclusively on novel, transformational therapeutics at discovery and pre-clinical stages.
our investments address critical needs in oncology, immunology, neuroscience, eye care, and aesthetics.
We offer our partners access to AbbVie’s vast internal network of experts in all phases of drug development, from drug discovery through successful commercialization.
|
|
Abingworth
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
rare diseases that target the endocrine system, chronic kidney disease, bacterial infections and viral infections, genetic diseases, cancer, Congenital Adrenal Hyperplasia, Polycystic Ovary Syndrome, CKD, kidney failure, Chronic Inducible Urticaria, atopic dermatitis, cholestatic pruritus, fanconi anemia, sickle cell disease, chronic granulomatous disease, SCID, rotavirus, shingles, norovirus, solid tumors, hematologic malignancies, rare diseases, oncology, inherited forms of blindness, orphan metabolic diseases, severe autoimmune, inflammatory diseases, solid tumors, breast cancer, Primary Biliary Cholangitis, Pre-clinical Phase completeDiabetic Hypoglycemia, gastrointestinal, neuroscience, hematology, rare genetics, Warts, Hypogammaglobulinemia, Infections and MyeloKathexis, Certain Chronic Neutropenic Disorders, CNS, inherited retinal disease, severe neurological diseases, chronic respiratory diseases, GERD, heartburn, non-erosive acid reflux
|
Cell therapies, Gene therapies, Large molecules (biologics), Microbiome therapies, Protein degradation, Small molecules and peptides, Vaccines
|
We strive to foster the creation of important new treatments for patients.
We follow a multi-pronged strategy with investments at all stages of product development across multiple disease areas.
Our portfolio is driven by patients in need, and opportunities to develop and commercialise important new treatment options for them. Our typical investment criterion are outlined in the box to the right.
Typical Investment Size
$15-$30m
Geography
Primarily US & Europe
Holding Period
3-8 years
Sectors
Biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, platform technologies.
Broad Strategic Approach
Biopharma companies in need of capital come with many different profiles. Some are startups seeking to discover new drugs based on emerging insights into underlying mechanisms of disease. Others may have begun that way, but now have drugs in clinical trials. Many are still privately held, while others are publicly traded. Some may even be established pharmaceutical companies looking for creative ways to fund expensive clinical trials.
Our strategies, described below, are designed to help companies in all these categories pursue their goal of developing novel and effective therapies for patients.
Seed & Early Stage
With over 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.
Development Stage
We also understand the different challenges faced by later-stage companies, both public and private, as their programs move through the clinic to market. Our Development Stage strategy is focused on these later-stage companies.
Clinical Co-Development
We have pioneered a new approach to partnering with pharmaceutical and biotech companies to help them develop effective new drugs and deliver them to patients in an accelerated manner.
|
|
Acorn Bioventures
|
New York
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million, $15 - $20 million
|
Europe, North America
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
dermatologic conditions, cancer, immuno-oncology, Parkinson's disease, Alzheimer's disease, oncology, cardiovascular disease, nervous system disorders, age-related macular degeneration (AMD), associated rare genetic diseases, severe autoimmune, inflammatory diseases, chronic respiratory diseases, solid cancer tumors, systemic debilitating diseases, leukemias, lymphomas, orphan pulmonary, fibrosis diseases, nonsegmental vitiligo, psoriasis, rheumatoid arthritis, bladder cancer, melanoma, precision
immunocytokine, Warts, Hypogammaglobulinemia, Infections, MyeloKathexis, Chronic Neutropenic Disorders, Waldenströms Macroglobulinemia, Multiple Myeloma, Pancreatic, Ovarian, TN Breast, Hematological, Ovarian Cancer, Endometrial Cancer
Fast Track Designation, major depressive disorder, focal onset seizure, Pain, Epilepsy, Depression, anemia, mastocytosis, gastrointestinal, Gaucher Disease,
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
Acorn Bioventures invests across stages in small-cap public and private biotechnology companies focused on bringing novel innovative medicines to patients. Our investment flexibility allows us to provide value across the entire spectrum from seed financings, cross-over financings, IPOs, registered direct offerings, PIPEs, open market purchases, etc.
Management teams of our portfolio companies are our long-term partners and we are proud to be part of the entrepreneurial and pioneering spirit in biotech. Acorn Bioventures is structured to be able to provide committed capital to companies through multiple rounds of financing.
Our investment process is based on fundamental research. We look for paradigm changing medical therapies, undiscovered or underappreciated assets, backed by outstanding teams.
We have over 35-year investment experience, including numerous structured public investments, in excess of forty investments in private biotech or medtech companies, and service on more than a thirty Boards. Most of the private investments went on to complete an IPO and some were acquired while private. Driven by their innovation in medicine, many of these companies have grown into very successful multi-billion-dollar exceptional enterprises with approved therapies.
Examples of recent and past private or small cap public investments include Anacor, Arena, Ascendis, Cardiff Oncology, Chiasma, Eidos (Bridge Bio), Eliem, Freeline, GW Pharma (Jazz Pharma), Neuron23, OnKure, Q32 Bio, Renovacor, Tesaro, etc.
This website is intended solely to provide information regarding Acorn Bioventures' potential capabilities with respect to prospective portfolio investments. No information on this website is intended as, and you should not consider it as, investment advice or tax, accounting or legal advice. Past performance is not a guarantee of future results. This website is not an offer to sell or a solicitation of any offer to buy any security in any Acorn Bioventures fund.
|
|
Adage Capital Management
|
Boston
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC), Commercial
|
$10 - $15 million, Over $20 million, $15 - $20 million
|
Asia, Europe, North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Series B-Z, IPO or Public, Series A
|
cancer, oral immunology, autoimmune, inflammatory disorders, neurodegenerative, viral diseases, cardiovascular diseases, chronic non-tuberculous mycobacterial (NTM) lung disease, solid tumors, myeloma, endometrial cancer, myelofibrosis, Recessive Dystrophic Epidermolysis Bullosa, Stargardt Disease, X-Linked Retinoschisis, Autosomal Dominant Optic Atrophy, Sanfilippo Syndrome Type A, Rett Syndrome, Infantile Batten Disease, sclerosis, ulcerative colitis, celiac disease, gastrointestinal disease, Crohn’s disease, dermatologic, rheumatologic diseases, neuroinflammatory diseases, Guillain-Barré Syndrome, Huntington’s Disease, lupus, anemia, diabetes, chronic pain, atopic dermatitis, psychiatric and neurological conditions, rare diseases, rare metabolic disorders, neuromuscular, neurological disorders, prostate cancer, ovarian cancer, genetic disease, cystic fibrosis, pain, sickle cell disease, beta thalassemia, Alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, Duchenne muscular dystrophy, Type 1 diabetes, melanoma, metastasis, hematologic, cardiovascular Disease, Polycythemia Vera, cholestasis, neurological and neuropsychiatric disorders, pulmonary disorders, severe Emphysema, Schizophrenia, Psychosis epilepsy. panic disorder, early Parkinson's disease, dementia, MDD, carcinoma, esophageal cancer, cough, lung cancer,
HIV-1 infection,
|
Cell therapies, Gene therapies, Large molecules (biologics), Microbiome therapies, Small molecules and peptides, Protein degradation, Vaccines
|
Adage Capital Management focuses on managing S&P 500 assets predominantly for endowments and foundations.
|
|
Aditum Bio
|
San Francisco
|
Both / no preference
|
Preclinical, Early-stage clinical (pre-POC), Discovery
|
$15 - $20 million, Over $20 million
|
North America
|
505(b)1
|
Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Series A
|
obesity, cardiometabolic disease, HIV, hepatitis b, hepatitis c, obesity, depression, substance abuse, renal disease, infectious diseases, mental health conditions, traumatic injuries, cerebral palsy, stroke, head trauma, multiple sclerosis, spinal cord injury, sarcopenic obesity, pediatric obesity, heart failure in obesity, Influenza A,
Human Rhinovirus,
BK Polyomavirus, Adenovirus
|
Cell therapies, Gene therapies, Small molecules and peptides
|
Drug development has reached an inflection point. Legacy drug development models are falling short in meeting those needs. Aditum Bio is dedicated to filling the gap through an alternative, patient-driven approach to acquiring and developing novel drug assets.
Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense. Aditum Bio stands apart in the biotech venture capital arena through our differentiated approach for identifying promising, clinic-ready therapies that offer value for underserved patient populations, in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases.
Harnessing our experienced in-house R&D domain experts as the foundation of our agile operating model, Aditum Bio is able to accelerate the formation and ramp-up of its portfolio companies. We augment each company's newly-established, dedicated leadership team with medical and scientific experts. Operating under the Aditum Bio umbrella in a lean and efficient management structure, portfolio companies are empowered to rapidly progress newly-acquired drug candidates into Phase 2 clinical trials.
Aditum Bio’s strategic advantage extends to its proven acumen for using an array of powerful technologies and digital tools throughout its portfolio companies to support clinical trial execution at the highest level of efficiency. Through our in-house technology capabilities and our extensive partnerships with leading solutions providers, we enable therapies to advance more quickly and at lower cost than in traditional R&D models.
|
|
Advent Life Sciences
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Europe
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z
|
cancer, osteoarthritis, inflammatory diseases, autoimmune, neurodegenerative disorders, life-threatening fungal diseases, neurological disorders, Idiopathic pulmonary fibrosis (IPF), chronic cough,
|
Gene therapies, Microbiome therapies, Small molecules and peptides, Vaccines
|
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.
We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
The companies in which we have invested since the year 2006 have discovered and developed, fifteen approved medicines and products to the benefit of patients, physicians and our investors.
Understanding the true essence of the innovation and product concept
its competitive relevance in an evolving environment, and the most meaningful value-creation steps along the way
working in open communication with founders and executives, sharing our diligence and our team’s insights, to refine their business and operating plans
and, together, agreeing the scientific and clinical approach, the matching operating plan, team development, syndication, and financing strategy – the five key elements to building a great biotech company.
|
|
Agent Capital
|
Cambridge
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic
|
Seed, Series A, Series B-Z
|
cancer, tumor, autoimmune disease, inflammatory disease, fibrotic disease, metabolic disease, hemophilia, cardiovascular disease, blood cancer, inflammatory bowel disease, fibrosis, primary sclerosing cholangitis, idiopathic pulmonary fibrosis, liver fibrosis, muscular dystrophies, skin disease, microcystic lymphatic malformations, gorlin syndrome, renal fibrosis, cardiac fibrosis, melanoma, liposarcoma, neuromuscular disease, chronic disease, COVID19, lymphoma, hematological cancer, urothelial cancer, blood disorder,
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines
|
Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.
Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.
At Agent Capital, we proactively guide biotech companies to milestones and exits.
With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward no matter the stage or investment type.
|
|
Aglaia Oncology Funds
|
Bilthoven
|
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
|
|
505(b)1
|
|
Therapeutic R&D, Diagnostic, Medical Device
|
IPO or Public
|
cancer, oncology, prostate cancer, breast cancer, solid tumors, cervical cancer, chronic HBV, COVID-19 infection, cell carcinoma, psoriasis, advanced malignancies, immunotherapy,
|
Cell therapies, Large molecules (biologics), Small molecules and peptides
|
Aglaia Oncology Funds is a financial service company that provides investment funds in the research of anti-cancer drugs.
The Aglaia team has decades of experience in cancer research and oncology drug development. Since 2004, Aglaia has built an excellent reputation in starting up biotech companies that focus on oncology drug development.
Aglaia is committed to define the strategic directions of the companies it invests in in close collaboration with innovators and entrepreneurs. Aglaia brings hands-on experience in designing research and development plans, ranging from early screening and animal feasibility studies through clinical studies.
Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, of which 6 were founded by Aglaia. Aglaia Growth Fund(s) further invest in selected portfolio companies. The experienced team has been involved in the development of more than 100 oncology products. The continuous strategic and operational involvement of the team with portfolio companies has contributed to a marked success rate in transitioning early-stage portfolio companies to clinical-stage companies. By doing so, Aglaia has de-risked and matured these companies up to the level at which they become attractive candidates for licensing, acquisition or IPO.
|
|
Aisling Capital
|
New York
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC), Commercial
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Series A, Series B-Z, IPO or Public
|
cancer, migraine, psychiatric disorders, narcolepsy, central nervous system disorders, oral desensitization immunotherapy, life-threatening diseases, depletion of cells, protein aggregates, and other disease-causing agents, viral diseases, solid tumors, hematologic malignancies, orphan metabolic diseases, chronic respiratory diseases, rare diseases, endocrine disease, genetic diseases
|
Cell therapies, Gene therapies, Large molecules (biologics), Microbiome therapies, Small molecules and peptides
|
Aisling Capital seeks to identify differentiated healthcare products, services and technologies that address unmet medical needs. Our business is to provide promising companies with meaningful capital resources and to assist them in achieving their growth objectives. We identify healthcare companies at a stage in their development where an infusion of capital and strategic assistance will significantly enhance the opportunities for success.
Aisling Capital makes investment decisions driven by fundamental assessment of scientific, regulatory, financial and commercial risks. Given our investment team’s broad skillset, we invest across the life sciences, including seed and venture financings of development-stage companies, small-cap publicly traded equities, structured debt and royalty deals and large-cap leveraged buyouts of profitable companies.
Aisling Capital takes an active approach to investing, working closely with portfolio companies to help them become value-building enterprises with multiple opportunities for exit. Our investment professionals collaborate with management teams and contribute expertise and experience to help determine and execute strategy, identify and evaluate business opportunities and address financial issues.
|
|
Alaska Permanent Fund
|
Juneau
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million
|
North America
|
505(b)1
|
Over $15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Series A, Series B-Z
|
genetic diseases, autoimmune, metabolic, oncology, infectious disease, immunology, diabetes, CNS, liver disease
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
Viewed as one of the largest, most effective, and globally-positioned institutional investors among U.S. investment plans, the Permanent Fund is also positioned to participate fully in the future economic opportunities in both industrialized and high-growth emerging markets. To that end, APFC is actively partnering with leading investment managers and institutional investors operating on each major continent with the objective of gaining access to the most compelling investment opportunities around the globe as they arise.
By adhering to an investment practice which ensures investment efficiency (whereby investment returns are compensated for the risks under taken), prudent diversification, and best-in-class access to compelling opportunities, APFC hopes to continue its history as being among the best-managed sovereign wealth funds in the world, all while helping to serve Alaska’s current and future generations for many decades to come.
APFC’s investment management strategy relies on the combination of both efficient asset allocation design and effective investment with in each asset class it manages. Generally, APFC employs a combination of internally managed direct investments alongside externally-managed fund investments in order to secure the best access to high-quality investment opportunities worldwide. Major asset classes include public equities, fixed-income, private equity, real estate, infrastructure, absolute return, risk parity strategies, and cash that are managed to outperform specific long-term growth and income targets. In addition, illiquid opportunities among APFC’s private equity , real estate, and infrastructure investments are underwritten to capture the benefits of an “illiquidity premium” that can prevail among these assets. In combination, this portfolio targets investment returns in excess of inflation (CPI) plus 5% or better on a long-term basis as well as compelling performance as measured against peers and market index benchmarks.
|
|
Alexandria Venture Investments
|
Pasadena
|
Both / no preference
|
Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
Atherosclerosis, Psoriasis/Rheumatoid Arthritis, Sepsis, Inflammatory Bowel Disease, Cancers, Tumors, Alzheimer's, Parkinson's, allergy, prostate cancer, breast cancer, Fibrosis, Celiac Disease, Migraine, CELIAC DISEASE, Anxiety, Schizophrenia, Schizophrenia, Chronic Spontaneous Urticaria, Anemia, Cardiac Friedreich’s Ataxia, Arrhythmogenic cardiomyopathy, Ulcerative Colitis, Crohn's Disease, Acute Myeloid Leukemia, Lymphoblastic Lymphoma,
|
Cell therapies, Gene therapies, Large molecules (biologics), Protein degradation, Small molecules and peptides
|
To create and grow life science ecosystem and clusters that ignite and accelerate the world's leading innovators in their noble pursuit to advance human health by curing disease and improving nutrition.
Alexandria has identified four critical components for life science clusters and companies to thrive: location, innovation, talent, and capital.
Our proven cluster model unites cutting-edge innovation with leading scientific and managerial talent and strategic investment capital in best-in-class locations immediately adjacent to the world’s top academic institutions.
|
|
Ally Bridge
|
Hong Kong
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, Over $20 million
|
North America, Asia
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Series A, Series B-Z, IPO or Public
|
cancer, back pain, serious disease, nasal breathing, pulmonary fibrosis, autoimmune, Alzheimer, Parkinson's disease, solid cancer tumors, kidney disease, severe human viral infections, pulmonary disorders, venous insufficiency, neuroscience diseases, severe emphysema
|
Cell therapies, Gene therapies, Large molecules (biologics), Radiopharmacueticals, Small molecules and peptides
|
We invest across the global healthcare industry and investments are made across the capital structure in one of two complementary strategies: private equity and public equity.
We seek to deliver superior returns through our understanding of value across private and public markets.
|
|
Altitude Life Science Ventures
|
Durango
|
Both / no preference
|
Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
North America
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D
|
Series A, Series B-Z
|
Chronic Inducible Urticaria, Atopic Dermatitis, Cholestatic Pruritus, Alzheimer’s, Schizophrenia, Parkinson’s Disease, Cancer, Solid Tumors, Chronic lymphocytic leukemia, Multiple myeloma, Non-Hodgkin lymphoma, Diabetes, Huntington’s disease, Pelizaeus-Merzbacher disease, sclerosis, Sickle cell disease, hepatitis B, Glycogen storage disease,
|
Cell therapies, Gene therapies, Protein degradation, Small molecules and peptides
|
Altitude Life Science Ventures seeks opportunities to invest in early stage life science companies within markets with significant demand and growth potential, and then backs the highest-quality teams in those markets to build defensible, strong, and long-term businesses. At Altitude, our scope of investment opportunities extends beyond prescription drugs to any commercial application of proprietary technology that originates from a key advance in biology or chemistry, including:
Therapeutics / Diagnostics
Medical Devices
Aesthetic and Medical Dermatology
Drug Delivery Platforms
Industrial / Chemical Reactions
Optical Displays
Agriculture / Plant Microbiome
DNA Sequencing
Pulmonary Delivery
we have developed a differentiated strategy which allows us to complement the contributions of our syndicate partners while conducting extended due diligence before making an investment decision.
|
|
Amgen Ventures
|
San Francisco
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Europe, Asia
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series B-Z, IPO or Public, Series A
|
solid tumors, heme, osteoporosis, cardiometabolic diseases, autoimmune, inflammatory disorders, chronic and episodic migraines, chronic kidney disease, neurodegenerative disorders, cancer, diabetic kidney disease, idiopathic pulmonary fibrosis, diseases of the bone marrow, chronic inflammatory diseases
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines
|
Amgen is harnessing our world-class capabilities to deliver more value to those we serve—providing better care and a better patient experience through integration of novel health technologies with our molecules. These technologies include diagnostics, drug formulations, delivery devices, and digital health tools.
Amgen Business Development transforms opportunities into breakthroughs by leveraging our unique capabilities with the innovative technologies and therapies of our partners. Our collaborative relationships with leading academic and medical institutions, technology companies, healthcare professionals, and patients ensure that we understand and address root causes of challenges at every stage in healthcare. Together, we can deliver life-changing therapies to patients around the globe.
The Corporate Strategy team leads projects that deliver on Amgen's corporate strategic plan. They partner and collaborate with leaders on special projects and synthesize competitive insights into actionable takeaways for senior leaders and the executive team.
|
|
AmorChem Ventures
|
Montréal
|
Follower investors / prefers to follow
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, Over $20 million
|
North America
|
505(b)1
|
$1 - 3 million, $5 - 15 million
|
Therapeutic R&D
|
Seed, Series A, Series B-Z
|
colon, terminal ileum, diabetic kidney disease, metabolic syndrome. idiopathic pulmonary disease
|
Small molecules and peptides
|
AmorChem is a leading early stage venture fund dedicated to creating the next generation of biotech companies from academic research.
At AmorChem our goal is to be the premier early-stage venture fund in Canada: building an active and collaborative community of biotech start-ups from academic research and fostering a new generation of passionate science entrepreneurs.
|
|
Amplitude Venture Capital
|
Montreal
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Middle East Africa Rest of the World
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D
|
Series A, Series B-Z, IPO or Public
|
inflammatory diseases, cancer, auto-immune, infectious diseases, genetic metabolic diseases, rare genetic diseases, solid and heme, neurological diseases, small cell lung cancer, neurodevelopmental disorders, Long QT Syndrome and potentially other arrhythmias, cardiovascular diseases, Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer, tumor cells
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
We are savvy investors and proven company builders who, at the core, are driven to bring the best healthcare innovations to market to help improve the lives of patients one patient at a time.
Our portfolio is the best example of how our team helps founders and entrepreneurs create, build, and grow their companies. This hands-on approach is hard-wired in the Amplitude culture as we know that investment capital alone is never enough. The Amplitude team is responsible for the initial investment or significant additional investment and value creation in the following companies while at BDC Capital and now at Amplitude.
|
|
Andera Partners
|
Paris
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
autoimmune, rare diseases, neuroendocrine, hard-to-treat cancers, congestive heart failure, rare endocrine, metabolic disorders, hypertension, psoriasis, Atopic Dermatitis, Urticaria, Interstitial Cystitis, hypoparathyroidism, acromegaly, primary hyperparathyroidism, humoral hypercalcemia of malignancy, blood cancers, inflammatory bowel disease, acute viral infection, CKD, Thrombotic Thrombocytopenic Purpura, acute ischemic stroke, Alzheimer's disease, cancer, inflammatory diseases, orphan diseases, CNS disorders, infectious diseases, head and neck squamous cell carcinoma, triple negative breast cancer, vascular calcification disorders, septic shock
|
Cell therapies, Large molecules (biologics), Radiopharmacueticals, Small molecules and peptides, Vaccines
|
We currently manage €4 billion, invested in around 300 companies in Europe and the United States. We support the development of these companies, their innovation and R&D projects, their growth and their international expansion.
We have an in-depth understanding of the challenges faced by growing companies. As experts in investment and business strategy, we like to see ourselves as sparring partners for entrepreneurs and management teams, supporting them in their projects: organic and inorganic growth, international development, innovation, recapitalisation, corporate governance and change management.
We offer several investment strategies to support:
Companies driving therapeutic and medical innovation in Europe and the United States: andera Life Sciences makes equity investments from €5m to €35m
Green innovative infrastructures in Europe and mainly in France: andera Infra makes equity investments from €5m to €30m
European SMEs and mid-caps with annual revenues between €10m and €500m:
– andera Croissance: €3m to €10m in equity financing
– andera Expansion: €10m to €25m in equity financing
– andera MidCap: €25m to €100m in equity financing
– andera Acto: €5m to €100m in mezzanine financing
|
|
Angelini Ventures
|
Rome
|
Follower investors / prefers to follow
|
Discovery
|
$5 - $10 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$1 - 3 million, $5 - 15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Seed, Series A
|
CNS disorders, neurodevelopmental disorders, mental health, epilepsy, brain disorders, aging,
|
Gene therapies, Small molecules and peptides
|
We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology
Our focus is on innovation in digital healthcare, connected medical devices, and life sciences
Our investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs.
|
|
Apollo Health Ventures
|
Berlin
|
Both / no preference
|
Discovery, Preclinical
|
$0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D
|
Seed, Series A
|
age-related diseases, rare diseases, heart failure diseases, neurological disorders, rare genetic and neurodegenerative diseases, cancer, tumor, Dravet syndrome and other rare epilepsies, ALS also known as Lou Gehrig’s disease, autism, Parkinson’s, Alzheimer’s,chronic liver disease
|
Cell therapies, Gene therapies, Microbiome therapies, Small molecules and peptides
|
Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself.
Our interventions target the underlying causes of aging as well as the age-related damage and dysfunction at the molecular, cellular, and tissue level.
We focus on therapeutics that target root causes of age-related diseases, allowing us to enable innovative treatment options.
|
|
Arboretum Ventures
|
Ann Arbor
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
lymphedema or venous diseases, prostate cancer, kidney disease, bladder cancer, glaucoma, breast cancer, autoimmune diseases, post-surgical pain management, recuperation
|
Cell therapies, Gene therapies, Small molecules and peptides, Large molecules (biologics)
|
A healthcare venture capital firm rooted in the Midwest
Our progressive strategy of investing in under-ventured geographies and sectors, coupled with our expertise in building deep relationships with entrepreneurs, executives, and investment partners across the healthcare industry, are significant factors contributing to our success.
Innovations that deliver meaningful improvements to patient outcomes and reduce health system costs
Groundbreaking opportunities in our sectors of focus: medical devices, life sciences tools & diagnostics, tech-enabled care delivery, and pharma adjacencies
Founders and CEOs with domain expertise who embrace capital efficiency and seek collaborative investment partners rather than passive financiers
Investments that span development and commercial stage but focus on Series A and B opportunities
Under-ventured opportunities, as it relates to geographies, teams, and sectors
|
|
ARCH Venture Partners
|
Chicago
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Asia, Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
neurological disorders, cancer, metastatic cancers, cardiovascular disease, autoimmune diseases, liver cancer, breast cancer, colon cancer, lung cancer, lymphoma, gene amplified cancers, inflammation, dementia, CNS disorders, aggressive and resistant cancer types, neuropsychiatric disorders, neurodegenerative diseases, MDD, asthma, rare genetic disorders, CNS diseases, complex diseases, solid tumors, liver diseases, rheumatological disorders, neuropsychiatric disorders, rheumatoid arthritis, ulcerative colitis, Crohn's disease, pancreatic cancer, diabetes,
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines
|
We’re catalyzing discoveries that prevent, detect, and cure disease.
Over 30 years, ARCH has backed disruptive science companies with as little as $50K to as much as hundreds of millions of dollars, per company.
We are not interested in following the crowd. We are contrarian, bold, and imaginative risk takers. We follow the science to found companies based on revolutionary technologies that can impact people’s lives.
We take a long-term view when building companies. That’s why we are flexible in our approach and size our portfolio company investments as needed. Our extended network of partners helps us build companies through the formation stages and grow to their full potential.
ARCH Strategic Partnerships (ASP) is an ARCH initiative for corporations building innovation-driven technology commercialization and business development practices globally.
We provide consulting services and foster relationships to help industry leaders collaborate with early-stage scientific innovators and bring cutting-edge discoveries to market. ASP team members share strategic insights gleaned from over three decades of experience building scientific ventures that have transformed industries.
|
|
Arix Bioscience
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million
|
Therapeutic R&D
|
Series A, Series B-Z, IPO or Public
|
immuno-oncology, hematologic diseases, rare blood disorders, inflammatory diseases, cancer, tumors, retinal degenerative diseases, sickle cell disease, atopic dermatitis, urticaria, interstitial cystitis, autoimmune disease, anemia, ovarian cancer, melanoma, liposarcoma, breast cancer, lung cancer, metastasis, bladder cancer,
|
Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines, Cell therapies
|
We focus on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide flexible, long term capital to help accelerate their ideas into important new treatments for patients.
We are science led investors, focusing on innovative technologies in areas of high unmet need. With our transatlantic footprint we have deep-routed networks across Europe and North America to source the best opportunities that offer meaningful therapies for patients.
Novel therapeutics with first or best in class approach. We focus on investing in high impact science, with the potential to dramatically improve outcomes for patients.
An experienced team with a proven track record along with established venture capital and biotech networks provide Arix with access to quality deals
Headquartered in London with an office in New York provides access to the best life science innovation across Europe and North America
Guided by the quality of the opportunity with a focus on late pre-clinical to clinical stage companies
|
|
Arkin Bio Ventures
|
Herzliya
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Middle East Africa Rest of the World
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z
|
endogenous disease-fighting mechanisms, liver diseases, viral diseases, cancer, tumor, myelodysplastic syndrome, AML, leukemia, Myelodysplastic syndromes, Myelofibrosis,
FID-anemia in MDS & MF,
Pulmonary arterial hypertension, chronic heart failure, Duchenne muscular dystrophy
|
Cell therapies, Large molecules (biologics), Small molecules and peptides
|
Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech, medical device, and digital health technologies. Our synergistic healthcare investments are focused on creating innovations that benefit humanity and enhance medical care.
We offer extensive experience, with a track record of successful healthcare investments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth.
It has always been Arkin Holdings clear policy to leverage the vast knowledge and experience of its management team, when selecting its investments. Each member of the management team has extensive experience in various aspects of pharmaceutical, life science and biotech companies - whether as an entrepreneur, a manager of large companies, or as an investor. This accumulated and significant expertise, is brought forward in all areas of business development, investment and financing decisions.
Far beyond just financial backing, Arkin Holdings provides its portfolio companies with hands-on professional and scientific accompaniment and mentoring in many fields such as drug development, clinical trials, regulation and ultimately commercialization.
|
|
Astellas Venture Management
|
Menlo Park
|
Both / no preference
|
Discovery, Preclinical
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Asia, Europe, North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z
|
cancer, immunology, autoimmunity, tumors, oncology, ophthalmology, metabolic, otology, genetic disease, infectious disease, breast cancer, gastric cancer, NSCLC, melanoma, ovarian, dilated cardiomyopathy, old myocardial infarction, diastolic hypertrophic cardiomyopathy
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. For over 15 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research.
Investment Targets We will make an investment in privately owned early-stage biotechnology company focused on therapeutics programs and platform technologies for drug discovery and development. Program stage should be in preclinical to be considered equity investment.
Areas of Interest Our areas of interest are innovative therapeutic approach which is close to R&D strategy of Astellas Pharma (see: https://www.astellas.com/en/innovation) and unprecedent treatment but that becomes realized in the near future. We prioritize companies with programs and technologies to fulfill unmet medical needs who have been wanting for.
What AVM Provides The strength of AVM lies in our “Pharma View” based on our long-standing experiences in the pharmaceutical industry. By providing our portfolio companies with invaluable information leveraging pharma expertise, we are able to support their growth. Moreover, we can be liaison between our portfolio companies and Astellas Pharma by helping them to facilitate a dialogue for future collaborations.
|
|
Atai Life Sciences
|
Munich
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC), Commercial
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$5 - 15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Series B-Z, IPO or Public
|
migraine, erectile dysfunction, schizophrenia, neurodegenerative brain diseases, opoid dependence, chronic pain, dimethyltryptamine, salvinorin A, TRD, PTSD, anorexia nervosa, MDD, cancer, chronic cluster headache, body dysmorphic disorder, severe TRD, bipolar disorder, suicidal ideation, autism, rumination
|
Large molecules (biologics), Small molecules and peptides
|
We are a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
We founded atai in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.
|
|
ATEM Capital Fund LP
|
New York
|
Follower investors / prefers to follow
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D
|
Series A, Series B-Z
|
rare endocrine, metabolic disorders, cancer, Hypoparathyroidism, Acromegaly, Humoral hypercalcemia of malignancy, Melanoma,
Lung Cancer, Negative Breast Cancer, Sarcomas,
|
Cell therapies, Large molecules (biologics), Small molecules and peptides
|
INVESTMENTSATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer. Our target technologies are breakthroughs with unmet clinical need, strong IP protection, and the appeal to become a must-have for strategic players. We completed many successful transactions with a superior return on invested capital in partnerships with the leading US and EU venture groups.
Fundamental factors fuel the steady growth of the healthcare markets worldwide despite any financial vulnerabilities, with the latest years setting a new sustainable record. Both public and private healthcare costs are constantly increasing in absolute and relative terms, notwithstanding financial vulnerabilities, thus creating stable multi-billion markets and second to none investment opportunities.
Landmark deal flow - of major like-minded US and Western Europe VC firms and selected private projects of successful serial entrepreneurs
Real-time insights - from the most connected Advisory Board into investment opportunities and emerging Big Pharma needs
Industrial-quality diligence - to optimize decision-making process and risk management
ATEM acts in strategic partnerships with the world’s leading venture firms and possesses critical mass, topnotch expertise, industrial quality diligence, and professional board-level control to identify superior technologies with healthy returns to investors
|
|
Avalon Ventures
|
La Jolla
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million
|
North America
|
505(b)1
|
$5 - 15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Series A, Series B-Z, Seed
|
tumor, cancer, immune-mediated, neurological diseases,
myeloproliferative disorders, lung cancer,
respiratory syncytial virus,
nonalcoholic steatohepatitis, bladder cancer, carcinoma, esophageal cancer, melanoma, colorectal cancer, hematological malignancies, cough, HIV-1 infection, oncology, mesothelioma, ovarian cancer, prostate cancer, COVID-19, solid tumors, gastric cancer, endometrial cancer, biliary tract cancer, oncology, thrombosis,
pulmonary arterial hypertension,
ulcerative colitis,
Schizophrenia, dengue fever, CNS, neurofibromatosis, breast cancer, brain tumors, metastases, cardiovascular, inflammatory diseases, immunological diseases,
|
Small molecules and peptides, Gene therapies, Large molecules (biologics), Peptide therapeutics, Vaccines
|
Avalon Ventures is a venture capital firm that has founded and/or funded more than 100 information technology and life sciences companies. The firm is passionate about backing talented entrepreneurs seeking to build market-leading companies. Throughout the firm’s 30 year tenure, Avalon’s long-standing and successful focus has been on seed and early-stage companies. All Avalon partners are seasoned entrepreneurs with experience in company formation, operations and value creation in the life science and tech sectors. A hallmark of Avalon is working closely with our companies on all aspects of its development – ranging from team building to strategy and operations to customer development.
|
|
Atlas Venture
|
Cambridge
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$1 - 3 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
non-alcoholic steatohepatitis, cancer, myeloma, retinal disorders, hematologic diseases, rare blood disorders, vision loss and blindness, inherited disease, solid tumors, erythropoietic porphyrias, anemia, inflammatory diseases, chronic kidney disease, central nervous system diseases, rare genetic disorders, autoimmune disorders, rare diseases, are and common liver, biliary, eye, CNS, cardiometabolic diseases, age-related macular degeneration (AMD), pediatric obesity, sarcopenic obesity, heart failure in obesity, anemia, serious muscle diseases, rare, cardiopulmonary disease, head and neck cancer, respiratory diseases, severe asthma, endometrial, gastric,
|
Cell therapies, Gene therapies, Large molecules (biologics), Protein degradation, Radiopharmacueticals, Small molecules and peptides
|
Biotech venture creation is a team endeavor.
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Atlas brings together talented entrepreneurs with experience in science, research, clinical development, business, and finance to build breakthrough biotech companies.
We are committed to fostering diversity at Atlas, in our portfolio companies, and in the broader biotech community and strive to support social justice.
Atlas companies are custom built to realize their scientific and business potential.
DISCOVER: Identifying true innovation from high-impact science.
DERISK: Proving and maturing the science and technology to guide clinical translation.
SHAPE: Crafting the right business model for each opportunity.
STRENGTHEN: Rolling up our sleeves to position our companies for successful drug development and exits in all market environments.
The opportunity determines the model—not the other way around. Our portfolio spans a spectrum of investment approaches from asset-centric product plays to big biology drug discovery platforms:
DRUG DISCOVERY PLATFORMS: Launching “big science” companies on the path to clinical and commercial success with multiple opportunities for liquidity. Examples include Avila, CoStim, IFM, Intellia, Magenta, Nimbus, miRagen, Padlock, and Surface.
ASSET-CENTRIC PRODUCT PLAYS: Bringing promising therapeutics to clinical proof-of-concept. Examples include Annovation, Arteaus, Delinia, LTI, Quartet, Rodin, Spero, Stromedix, and Zafgen.
|
